Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Eur Urol. 2021 Mar 27;80(1):71–81. doi: 10.1016/j.eururo.2021.03.005

Table 3 –

Completed but unpublished clinical trials in prostate cancer with drugs targeting epigenetic factors

S. no. Drug Target Combination Phase Indication Trial identifier Status
1 ZEN003694 BET 1 Metastatic castration-resistant prostate cancer NCT02705469 Completed
2 LBH589 HDAC Bicalutamide 1, 2 Metastatic castration-resistant prostate cancer NCT00878436 Completed
3 LBH589 HDAC External beam radiotherapy 1 Localized prostate cancer NCT00670553 Completed
4 LBH589 HDAC 2 Metastatic castration-resistant prostate cancer NCT00667862 Completed
5 LBH589 HDAC Docetaxel/prednisone 1 Castration-resistant prostate cancer NCT00663832 Completed
6 SAHA HDAC Bicalutamide, goserelin acetate, or leuprolide acetate 2 Localized prostate cancer NCT00589472 Completed
7 SAHA HDAC 2 Mtastatic castration-resistant prostate cancer NCT00330161 Completed
8 SAHA HDAC 1 Metastatic castration-resistant prostate cancer NCT00005634 Completed
9 MS-275 HDAC 1 Metastatic castration-resistant prostate cancer NCT00020579 Completed
10 Azacitidine DNMT 2 Metastatic or nonmetastatic castration-resistant prostate cancer NCT00384839 Completed
11 Azacitidine DNMT Sodium phenylbutyrate 2 Metastatic castration-resistant prostate cancer NCT00006019 Completed

BET = bromodomain and extraterminal; DNMT = DNA methyltransferase; HDAC = histone deacetylase.